Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liposyn II is a sterile, nonpyrogenic fat emulsion for intravenous administration, developed by Abbott Laboratories. It is composed of a 1:1 mixture of safflower oil and soybean oil, providing a source of essential fatty acids (linoleic and alpha-linolenic acids) and calories for patients requiring parenteral nutrition. In the context of patients with Acquired Immunodeficiency Syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP), Liposyn II has been investigated for its clinical effectiveness and its potential impact on immunologic function and HIV viral load. The emulsion is metabolized by the enzyme lipoprotein lipase, releasing free fatty acids that are used for energy or incorporated into cell membranes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Liposyn II.